Drug interactions with rifampicin: well known but not considered?

被引:1
|
作者
Strobach, Dorothea [1 ]
机构
[1] Univ Hosp Munich, Hosp Pharm, D-81377 Munich, Germany
关键词
D O I
10.1136/ejhpharm-2013-000314
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives Enquiries to the drug information centre revealed that clinicians were not aware of the importance of rifampicin drug interactions. We conducted a short time study to demonstrate the relevance of these interactions in the clinical setting today. Methods Over a total period of 4 weeks (two 2-week periods) we identified patients on rifampicin, performed a drug interaction test for their complete medication regime and analysed the results for severity of drug interactions. Results A total of 137 potential drug interactions were found in 26 patients, including 6 contraindications. For additional 80 combinations, treatment adjustment was required or probably necessary. Most interactions had not been considered for the patient, including all contraindications and drug interactions with anti-infectives. Conclusions Rifampicin drug interactions are of high relevance in the clinical setting today. However, clinicians failed to consider this issue for all patients. An individual drug interaction test is recommended for all patients given rifampicin. This is especially important when electronic patient records with integrated drug interaction tests are not available.
引用
收藏
页码:368 / 370
页数:3
相关论文
共 50 条
  • [21] A pilot study on the impact of known drug-drug interactions in cancer patients
    Ussai, Silvia
    Petelin, Riccardo
    Giordano, Antonio
    Malinconico, Mario
    Cirillo, Donatella
    Pentimalli, Francesca
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2015, 34
  • [22] Clinical Pharmacology of Bulevirtide: Focus on Known and Potential Drug-Drug Interactions
    Billi, Martina
    Soloperto, Sara
    Bonora, Stefano
    D'Avolio, Antonio
    De Nicolo, Amedeo
    PHARMACEUTICS, 2025, 17 (02)
  • [23] Are Well Known Phase Diagrams Really Well Known ?
    Dinnebier, Robert E.
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2005, 61 : C45 - C46
  • [24] How is Parkinson's treated and what drug Interactions need to be considered?
    Prell, T.
    ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2024, 57 : S126 - S126
  • [25] PHARMACOKINETIC INTERACTIONS WITH RIFAMPICIN
    ZILLY, W
    BREIMER, DD
    RICHTER, E
    CLINICAL PHARMACOKINETICS, 1977, 2 (01) : 61 - 70
  • [26] Editorial: Biofilm and Food: Well- and Lesser-Known Interactions
    Budroni, Marilena
    Torija, Maria-Jesus
    Moreno-Garcia, Jaime
    Zara, Giacomo
    FRONTIERS IN MICROBIOLOGY, 2022, 13
  • [27] Tibolone-induced acute hepatitis: Well-known drug, little-known complication
    Macedo, Guilherme
    Silva, Marco
    Vilas-Boas, Filipe
    Lopes, Susana
    Peixoto, Armando
    Carneiro, Fatima
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2017, 40 (04): : 298 - 300
  • [28] Desoxypipradrol a new (already well known) Designer Drug A Case Series
    Mueller, D.
    Angerer, V.
    Auwaerter, V.
    Neurath, H.
    Liebetrau, G.
    Just, S.
    Kithinji, J.
    Hermanns-Clausen, M.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2016, 141 (13) : 951 - 953
  • [29] Predicting drug-drug interactions between ainuovirine and rifampicin plus isoniazid using PBPK modelling
    Lu Hongzhou
    Meng Xianmin
    Qin Hong
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 : 17 - 18
  • [30] Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
    Maiara Camotti Montanha
    Francesc Fabrega
    Alice Howarth
    Nicolas Cottura
    Hannah Kinvig
    Fazila Bunglawala
    Andrew Lloyd
    Paolo Denti
    Catriona Waitt
    Marco Siccardi
    Clinical Pharmacokinetics, 2022, 61 : 375 - 386